Authors
Hendryck A Gellineau, Addison M Duda, Zachary J Mast, Sarah S Angle, Andrew D Ladhani, Lin X Chen, Katherine J Franz, Thomas J Meade
Published in
ACS infectious diseases. Volume 12. Issue 11. Pages 3705-3717. Nov 13, 2026.
Abstract
Antibiotic resistance is a critical public health concern, with approximately 2.8 million Americans infected with antibiotic-resistant bacteria annually and over 35,000 deaths in the United States alone. Of particular concern are Enterobacterales that express metallo-β-lactamases (MBLs), bacteria that cause nosocomial infections and exhibit resistance to most β-lactam drugs. The zinc-containing active sites of MBLs differ from those of serine β-lactamases, making current clinical inhibitors ineffective. No FDA-approved MBL inhibitors exist, leaving a critical gap in therapeutics for MBL-expressing Enterobacterales infections. Herein, we biochemically and spectroscopically demonstrate irreversible inhibition of the metallo-β-lactamase NDM-1 by a subset of cobalt(III) Schiff base complexes (Co(III)-sb). Crystallography and 59Co NMR experiments show that inactivation efficiency is dependent on axial and equatorial ligand identity. While Co(III)-sb exhibits NDM-1 inhibition, chemical modification is required to enable complexes to cross the Gram-negative envelope. These findings establish Co(III)-sb complexes as a novel scaffold for the development of MBL inhibitors.
PMID:
43023865
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0